Table 2.
Tumor characteristics of index screen-detected cancers, stratified by discordant and concordant scores in BreastScreen Norway
| All (n = 3024) | Discordant scores (n = 697) | Concordant positive scores (n = 2327) | p value* | |
|---|---|---|---|---|
| Histopathological characteristics | ||||
| Histopathological type | < 0.001 | |||
| Ductal carcinoma in situ | 553 (18.3) | 176 (25.3) | 377 (16.2) | |
| Invasive carcinoma of NST | 2106 (69.6) | 433 (62.1) | 1673 (71.9) | |
| Invasive lobular carcinoma | 240 (7.9) | 64 (9.2) | 176 (7.6) | |
| Other invasive carcinoma | 125 (4.1) | 24 (3.4) | 101 (4.3) | |
| Invasive tumors | 2471 (81.7) | 521 (74.8) | 1950 (83.8) | < 0.001 |
| Tumor diameter, median (IQR), mm | 13 (9–20) | 11 (8 – 17) | 14 (9 – 20) | < 0.001 |
| Data not available | 52 | 9 | 43 | |
| Histological grade | < 0.001 | |||
| Grade 1 | 752 (30.8) | 195 (38.0) | 557 (28.9) | |
| Grade 2 | 1163 (47.6) | 251 (48.9) | 912 (47.3) | |
| Grade 3 | 528 (21.6) | 67 (13.1) | 461 (23.9) | |
| Data not available | 28 | 8 | 20 | |
| Lymph node positive | 534 (22.1) | 83 (16.4) | 451 (23.6) | 0.001 |
| Data not available | 52 | 16 | 36 | |
| Immunohistochemical subtypes | 0.072 | |||
| Luminal A–like (ER+/PR+/Her2−) | 1358 (63.6) | 310 (69.0) | 1048 (62.1) | |
| Luminal B–like Her2− (ER+/PR−/Her2−) | 311 (14.6) | 57 (12.7) | 254 (15.1) | |
| Luminal B–like Her2+ (ER+/PR±/Her2+) | 264 (12.4) | 44 (9.8) | 220 (13.0) | |
| Her2+ (ER−/PR−/Her2+) | 87 (4.1) | 19 (4.2) | 68 (4.0) | |
| Triple negative (ER−/PR−/Her2−) | 116 (5.4) | 19 (4.2) | 97 (5.7) | |
| Data not available | 335 | 72 | 263 | |
Unless otherwise specified, data are presented as numbers with percentage in parenthesis
IQR interquartile range, NST no special type, ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor
*Overall p value for association between discordant/concordant scores and the different tumor characteristics